Project Grant R21AG093575
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $393K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $452,375 on January 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of semaphorin 3A in microglial activation and Alzheimer's disease pathology. The research will determine the functional role and mechanistic basis for semaphorin 3A–mediated regulation of microglial activation in Alzheimer's disease. Building on preliminary findings using human induced pluripotent...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $100,228 on February 18, 2027, under the Aging Research program (CFDA 93.866) for epigenetic regulation research on microglial dysfunction in Alzheimer's disease. The award funds laboratory research investigating how the protein ARID5B regulates histone modifications that influence microglial identity and function in Alzheimer's disease pathogenesis. The recipient will use CRISPR/Cas9 and CRISPR...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded The Trustees of Columbia University in the City of New York $475,377 under the Aging Research program (CFDA 93.866) for a project period from September 5, 2025, through August 31, 2027. The award supports research to determine the functional significance of microglial FOXO3 (Forkhead Box O-3) transcription factor in Alzheimer's disease (AD) pathobiology. The project addresses a critical gap in understanding how...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded a $2,957,210 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) on September 15, 2025, for research extending through August 31, 2029, under the Aging Research program (CFDA 93.866). The project, titled "Deciphering the Role of CD44 Astrocytes in Alzheimer's Disease," delivers comprehensive biomedical research aimed at understanding the molecular...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $511,574 on July 1, 2026, under the Aging Research program (CFDA 93.866) to develop statistical methods for precision health management in high-risk Alzheimer's disease populations. The recipient will conduct three integrated research activities. Aim 1 involves evidence synthesis through semi-automated systematic review and meta-analyses of published studies to synthesize evidence on prognostic...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $690,898 on September 15, 2026, under the Aging Research program (CFDA 93.866) to conduct functional genetic analyses of healthspan in humans. The recipient will identify shared genetic architecture underlying age-related diseases and aging-related traits, experimentally validate the regulatory roles of healthspan-associated non-coding variants and their target genes, and elucidate molecular...
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $230,388 on March 4, 2026, under the Aging Research program (CFDA 93.866) to dissect the role of the PICALM/EED locus on myeloid cells in Alzheimer's disease. The recipient will conduct research to understand how an Alzheimer's disease risk enhancer on chromosome 11 influences expression of two target genes—PICALM (phosphatidylinositol binding clathrin assembly protein) and EED (embryonic ectoderm development)—and to...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $529,744 on February 15, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of entorhinal cortex hyperactivity, neuroinflammation, and tau pathology progression in Alzheimer's disease. The research will use two-photon microscopy and chemogenetic manipulation to test three central hypotheses: that entorhinal cortex layer 2 neuronal hyperactivity drives disease...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $735,598 on July 15, 2026, under the Aging Research program (CFDA 93.866) to enhance research capacity for addressing Alzheimer's disease and related dementias and metal-induced cognitive decline in an aging cohort in Bangladesh. The award funds research investigating how chronic exposure to neurotoxic metal mixtures—including arsenic, lead, cadmium, manganese, and copper—influences cognitive...
- The National Institute on Aging awarded $15.924 million to The Trustees of Columbia University in the City of New York on September 15, 2025, under the Aging Research program (CFDA 93.866) to investigate SORL1 gene variants and their role in Alzheimer's disease pathogenesis. The award extends through May 31, 2030, with place of performance in New York, New York. The project addresses the pathogenic mechanisms of hundreds of SORL1 variants, the fourth gene identified as causal in Alzheimer's...